Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281768861> ?p ?o ?g. }
- W4281768861 endingPage "578.e3" @default.
- W4281768861 startingPage "568" @default.
- W4281768861 abstract "•Healthcare workers with heterologous COVID-19 vaccination were studied•Inoculation orders of heterologous vaccines affected serum neutralization breadth•Potency of heterologous booster vaccine was associated with neutralization breadth•Total neutralizing antibody levels were not associated with inoculation orders Many people around the world have received different types of COVID-19 vaccines in their two-dose vaccination schedules for various reasons. However, it is not clear whether the inoculation order of such heterologous vaccines was associated with subsequent immune responses. Here, an international team of physicians and scientists from China and the United States studied a cohort of healthcare workers who were among the earliest recipients of heterologous COVID-19 vaccination. The authors found that the inoculation order of heterologous vaccines was associated with the capability of neutralizing SARS-CoV-2 variants but not the original strain that the vaccines were based on. The results suggested that using heterologous booster vaccines with high potency could be a cost-efficient way to elicit protective immunity against future variants. BackgroundEmerging evidence suggests heterologous prime-boost COVID-19 vaccination as a superior strategy than homologous schedules. Animal experiments and clinical observations have shown enhanced antibody response against influenza variants after heterologous vaccination; however, whether the inoculation order of COVID-19 vaccines in a prime-boost schedule affects antibody response against SARS-CoV-2 variants is not clear.MethodsWe conducted immunological analyses in a cohort of health care workers (n = 486) recently vaccinated by three types of inactivated COVID-19 vaccines under homologous or heterologous prime-boost schedules. Antibody response against ancestral SARS-CoV-2 (Wuhan-Hu-1) was assessed by total antibody measurements, surrogate virus neutralization tests, and pseudovirus neutralization assays (PNA). Furthermore, serum neutralization activity against SARS-CoV-2 variants of concern was also measured by PNA.FindingsWe observed strongest serum neutralization activity against the widely circulating SARS-CoV-2 variant B.1.617.2 among recipients of heterologous BBIBP-CorV/CoronaVac and WIBP-CorV/CoronaVac. In contrast, recipients of CoronaVac/BBIBP-CorV and CoronaVac/WIBP-CorV showed significantly lower B.1.617.2 neutralization titers than recipients of reverse schedules. Laboratory tests revealed that neutralizing activity against common variants but not the ancestral SARS-CoV-2 was associated with the inoculation order of heterologous prime-boost vaccines. Multivariable regression analyses confirmed this association after adjusting for known confounders.ConclusionsOur data provide clinical evidence of inoculation order-dependent expansion of neutralizing breadth against SARS-CoV-2 in recipients of heterologous prime-boost vaccination and call for further studies into its underlying mechanism.FundingNational Key R&D Program of China, National Development and Re-form Commission of China, National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Commission, and US Department of Veterans Affairs. Emerging evidence suggests heterologous prime-boost COVID-19 vaccination as a superior strategy than homologous schedules. Animal experiments and clinical observations have shown enhanced antibody response against influenza variants after heterologous vaccination; however, whether the inoculation order of COVID-19 vaccines in a prime-boost schedule affects antibody response against SARS-CoV-2 variants is not clear. We conducted immunological analyses in a cohort of health care workers (n = 486) recently vaccinated by three types of inactivated COVID-19 vaccines under homologous or heterologous prime-boost schedules. Antibody response against ancestral SARS-CoV-2 (Wuhan-Hu-1) was assessed by total antibody measurements, surrogate virus neutralization tests, and pseudovirus neutralization assays (PNA). Furthermore, serum neutralization activity against SARS-CoV-2 variants of concern was also measured by PNA. We observed strongest serum neutralization activity against the widely circulating SARS-CoV-2 variant B.1.617.2 among recipients of heterologous BBIBP-CorV/CoronaVac and WIBP-CorV/CoronaVac. In contrast, recipients of CoronaVac/BBIBP-CorV and CoronaVac/WIBP-CorV showed significantly lower B.1.617.2 neutralization titers than recipients of reverse schedules. Laboratory tests revealed that neutralizing activity against common variants but not the ancestral SARS-CoV-2 was associated with the inoculation order of heterologous prime-boost vaccines. Multivariable regression analyses confirmed this association after adjusting for known confounders. Our data provide clinical evidence of inoculation order-dependent expansion of neutralizing breadth against SARS-CoV-2 in recipients of heterologous prime-boost vaccination and call for further studies into its underlying mechanism." @default.
- W4281768861 created "2022-06-13" @default.
- W4281768861 creator A5001716616 @default.
- W4281768861 creator A5003642180 @default.
- W4281768861 creator A5005906240 @default.
- W4281768861 creator A5006080858 @default.
- W4281768861 creator A5008118297 @default.
- W4281768861 creator A5009907265 @default.
- W4281768861 creator A5012278873 @default.
- W4281768861 creator A5026865430 @default.
- W4281768861 creator A5030093353 @default.
- W4281768861 creator A5033054535 @default.
- W4281768861 creator A5034604785 @default.
- W4281768861 creator A5036891682 @default.
- W4281768861 creator A5039727047 @default.
- W4281768861 creator A5045534834 @default.
- W4281768861 creator A5047183840 @default.
- W4281768861 creator A5048635616 @default.
- W4281768861 creator A5053045291 @default.
- W4281768861 creator A5064715870 @default.
- W4281768861 creator A5066237802 @default.
- W4281768861 creator A5067940339 @default.
- W4281768861 creator A5076699095 @default.
- W4281768861 creator A5079262483 @default.
- W4281768861 creator A5083637695 @default.
- W4281768861 creator A5084571872 @default.
- W4281768861 creator A5084817298 @default.
- W4281768861 creator A5084926998 @default.
- W4281768861 date "2022-08-01" @default.
- W4281768861 modified "2023-10-18" @default.
- W4281768861 title "Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines" @default.
- W4281768861 cites W1973449439 @default.
- W4281768861 cites W2037211123 @default.
- W4281768861 cites W2050241047 @default.
- W4281768861 cites W2947826795 @default.
- W4281768861 cites W2979641742 @default.
- W4281768861 cites W3022917947 @default.
- W4281768861 cites W3034173374 @default.
- W4281768861 cites W3043431476 @default.
- W4281768861 cites W3045724532 @default.
- W4281768861 cites W3046657126 @default.
- W4281768861 cites W3102328262 @default.
- W4281768861 cites W3126657865 @default.
- W4281768861 cites W3133980772 @default.
- W4281768861 cites W3135411054 @default.
- W4281768861 cites W3139040592 @default.
- W4281768861 cites W3153636933 @default.
- W4281768861 cites W3160471157 @default.
- W4281768861 cites W3161183609 @default.
- W4281768861 cites W3169082905 @default.
- W4281768861 cites W3172858351 @default.
- W4281768861 cites W3177694513 @default.
- W4281768861 cites W3177804396 @default.
- W4281768861 cites W3177819637 @default.
- W4281768861 cites W3178592334 @default.
- W4281768861 cites W3180561052 @default.
- W4281768861 cites W3182094313 @default.
- W4281768861 cites W3186217635 @default.
- W4281768861 cites W3190206472 @default.
- W4281768861 cites W3192494915 @default.
- W4281768861 cites W3206318896 @default.
- W4281768861 cites W3217055156 @default.
- W4281768861 cites W4205240144 @default.
- W4281768861 cites W4205294642 @default.
- W4281768861 cites W4205497912 @default.
- W4281768861 cites W4207040879 @default.
- W4281768861 cites W4210908142 @default.
- W4281768861 cites W4214623605 @default.
- W4281768861 cites W4225854071 @default.
- W4281768861 doi "https://doi.org/10.1016/j.medj.2022.05.003" @default.
- W4281768861 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35679856" @default.
- W4281768861 hasPublicationYear "2022" @default.
- W4281768861 type Work @default.
- W4281768861 citedByCount "2" @default.
- W4281768861 countsByYear W42817688612022 @default.
- W4281768861 countsByYear W42817688612023 @default.
- W4281768861 crossrefType "journal-article" @default.
- W4281768861 hasAuthorship W4281768861A5001716616 @default.
- W4281768861 hasAuthorship W4281768861A5003642180 @default.
- W4281768861 hasAuthorship W4281768861A5005906240 @default.
- W4281768861 hasAuthorship W4281768861A5006080858 @default.
- W4281768861 hasAuthorship W4281768861A5008118297 @default.
- W4281768861 hasAuthorship W4281768861A5009907265 @default.
- W4281768861 hasAuthorship W4281768861A5012278873 @default.
- W4281768861 hasAuthorship W4281768861A5026865430 @default.
- W4281768861 hasAuthorship W4281768861A5030093353 @default.
- W4281768861 hasAuthorship W4281768861A5033054535 @default.
- W4281768861 hasAuthorship W4281768861A5034604785 @default.
- W4281768861 hasAuthorship W4281768861A5036891682 @default.
- W4281768861 hasAuthorship W4281768861A5039727047 @default.
- W4281768861 hasAuthorship W4281768861A5045534834 @default.
- W4281768861 hasAuthorship W4281768861A5047183840 @default.
- W4281768861 hasAuthorship W4281768861A5048635616 @default.
- W4281768861 hasAuthorship W4281768861A5053045291 @default.
- W4281768861 hasAuthorship W4281768861A5064715870 @default.
- W4281768861 hasAuthorship W4281768861A5066237802 @default.
- W4281768861 hasAuthorship W4281768861A5067940339 @default.
- W4281768861 hasAuthorship W4281768861A5076699095 @default.